• Thorpe, (1985) "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera et al (ed.s), pp. 475-506). (justia.com)
  • 21:183-87) and monoclonal antibodies (mAbs) as well as drug-linking and drug-releasing properties (Lambert, J. (2005) Curr. (justia.com)
  • Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies - The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. (patentsencyclopedia.com)
  • Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. (abcam.com)
  • FAP shares substrate specificity with prolyl oligopeptidase (PREP), studied in (neuro)inflammation and neurodegeneration as well as cancer. (inra.fr)
  • Hexokinase (HXK) is the only plant enzyme that phosphorylates glucose (Glc), so it is key to fueling several metabolic pathways depending on their substrate specificity, metabolite regulatory responses and subcellular localization. (biomedcentral.com)
  • In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. (patsnap.com)
  • The present invention relates to an anti-tyrosinase antibody for inhibiting tyrosinase and use thereof, and more particularly, to an anti-tyrosinase antibody including a heavy chain CDR and a light chain CDR of specific sequences, or an antigen-binding fragment thereof. (justia.com)
  • The present invention relates to an anti-tyrosinase antibody for inhibiting tyrosinase and use thereof. (justia.com)
  • An object of the present invention is to provide an anti-tyrosinase antibody for inhibiting tyrosinase or an antigen-binding fragment thereof. (justia.com)
  • Another object of the present invention is to provide a fusion anti-tyrosinase antibody or an antigen-binding fragment thereof in which a TAT peptide is further bound to the anti-tyrosinase antibody or antigen-binding fragment thereof. (justia.com)
  • Still another object of the present invention is to provide a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a recombinant expression vector containing the nucleic acid molecule, and a cell transformed with the recombinant expression vector. (justia.com)
  • Still another object of the present invention is to provide a composition for detecting a tyrosinase antigen containing the antibody or antigen-binding fragment thereof as an active ingredient. (justia.com)
  • Still another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin pigmentation disorders or a composition for diagnosing skin pigmentation disorders containing the antibody or antigen-binding fragment thereof as an active ingredient, or a method for providing information necessary for diagnosing skin pigmentation disorders. (justia.com)
  • and a heavy chain variable region including a heavy chain CDR1 consisting of an amino acid sequence represented by SEQ ID NO: 4, a heavy chain CDR2 consisting of an amino acid sequence represented by SEQ ID NO: 5, and a heavy chain CDR3 consisting of an amino acid sequence represented by SEQ ID NO: 6, or an antigen-binding fragment thereof. (justia.com)
  • In addition, the present invention provides a fusion anti-tyrosinase antibody or an antigen-binding fragment thereof in which a TAT peptide represented by SEQ ID NO: 7 is further bound to the antibody or antigen-binding fragment thereof. (justia.com)
  • The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. (patsnap.com)
  • The invention relates generally to antibodies engineered with reactive cysteine residues and more specifically to antibodies with therapeutic or diagnostic applications. (justia.com)
  • The invention also relates to methods of using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. (justia.com)
  • The invention further relates to the use the novel antibody conjugates, and a kit comprising the same. (trea.com)
  • B cells, a subset of white blood cells, rapidly synthesize and secrete immunoglobulin E (IgE), a class of antibody that binds to antigens, the foreign proteins. (wikipedia.org)
  • Rapid and comprehensive analysis of putative proteinous allergens ( allergenome ) by applying such a proteomic strategy … With allergenomics, we can not only detect and assign the putative allergens (proteins specifically interacting with IgE antibodies in a patient's blood) in a short time, but also analyze the quantitative and qualitative change of the antigens, depending on the surroundings and environmental conditions of an allergenic causative. (genomicglossaries.com)
  • In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. (patentsencyclopedia.com)
  • Despite an evolutionary distance of at least 1.5 to 2.0 billion years, the deduced Gau proteins share some conserved amino acid signatures and structure, which suggests a possible conserved function. (biomedcentral.com)
  • Immunohistochemical analyses using an anti-Gau monoclonal antibody revealed strict co-localization of Gau proteins and a mitochondrial marker. (biomedcentral.com)
  • Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. (justia.com)
  • The use of antibody-drug conjugates (ADC), i.e. immunoconjugates, for the local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumor cells in the treatment of cancer (Lambert, J. (2005) Curr. (justia.com)
  • Drug moieties used in antibody drug conjugates include bacterial protein toxins such as diphtheria toxin, plant protein toxins such as ricin, small molecules such as auristatins, geldanamycin (Mandler et al (2000) J. of the Nat. (justia.com)
  • Specifically, the invention provides novel antibody conjugates suitable for use in Discrete Fluorescence Quenching Displacement Immunoassays and methods for producing these antibody conjugates. (trea.com)
  • This FRET-based homogeneous immunoassay consists of a dark-quencher labeled antibody and a fluorescently labeled peptide. (trea.com)
  • Both the analyte and the peptide are mixed together and compete in binding the subsequently added antibody. (trea.com)
  • When the peptide is bound by the antibody, the dark quencher and the fluorophore are in spatial proximity, resulting into a reduced fluorescence signal. (trea.com)
  • In homogeneous immunoassays, the antibody reacts with the analyte in solution, which allows much faster assay times. (trea.com)
  • A particle according to claim 1, further comprising the nucleic acid sequence encoding die protease cleavage signal. (sumobrain.com)
  • vi)a nucleic acid sequence according to any of (i) and (ii) which is degenerate as a result of the genetic code. (allindianpatents.com)
  • The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. (patsnap.com)
  • Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. (justia.com)
  • Performing an HCV RNA test whenever an HCV antibody test is reactive (complete testing) is critical to achieve national HCV elimination goals. (cdc.gov)
  • When an HCV antibody test is reactive and no HCV RNA test is performed, testing is considered incomplete. (cdc.gov)
  • Identification of such tumor-associated cell surface antigen polypeptides, i.e. tumor associated antigens (TAA), allows specific targeting of cancer cells for destruction via antibody-based therapies. (justia.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
  • Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. (patsnap.com)
  • This method can generate tens of billions of copies of a particular DNA fragment (the sequence of interest, DNA of interest, or target DNA) from a DNA extract (DNA template). (intechopen.com)
  • Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. (patentsencyclopedia.com)
  • When the multispecific antagonist comprises a combination of separate antibodies, combinations are excluded where one of said antibodies targets a B-cell antigen and the other antibody targets a T-cell, plasma cell, macrophage or inflammatory cytokine and combinations are also excluded where one of said antibodies targets CD20 and the other antibody targets C3b or CD40. (patentsencyclopedia.com)
  • In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen. (patentsencyclopedia.com)
  • Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed. (justia.com)
  • Source: serum and amino of dispersion of small compounds. (augenta.net)
  • The cysteine engineered antibodies may be conjugated with chemotherapeutic drugs, toxins, affinity ligands such as biotin, and detection labels such as fluorophores. (justia.com)
  • Additionally, homogeneous immunoassays only require one analyte specific antibody, which makes them suitable for detecting smaller biomarkers. (trea.com)
  • Additionally, we demonstrated that ZmHXK4-6 and ZmHXK9 are located in the mitochondria and their location relies on the first 30 amino acids of the N-terminal domain. (biomedcentral.com)
  • In the field of immunodiagnostics, antibodies are used to quantify clinical biomarkers in complex biological samples like blood (Wild, 2013). (trea.com)
  • Among these imaging techniques, nuclear imaging (including single photon emission computed tomography and positron emission tomography) remains the premier clinical method owing to their high specificity and sensitivity. (oncotarget.com)
  • total book of area of heart and the recipient of congestive versus sense amino will also prove Randomized. (augenta.net)
  • Compared to genomics and transcriptomics, proteomics approaches have, to date, provided comparatively less in-depth coverage of the target analyte due to increased complexity and technical demands of analyzing amino acid polymers versus nucleic acid polymers. (emtherapro.com)
  • Transmembrane or otherwise tumor-associated polypeptides specifically expressed on the surface of cancer cells as compared to normal, non-cancerous cell(s) have been identified as cellular targets for cancer diagnosis and therapy with antibodies. (justia.com)
  • The so-called Fluorescence Quenching Immunoassay uses two antibodies: one analyte specific antibody and one fluorophore specific antibody, whereby binding of the fluorophore specific antibody to the fluorophore reduces the fluorescence intensity. (trea.com)
  • By adding additional unlabeled analyte, via applying a sample, the steady state shifts and more fluorescence signal can be quenched by the fluorophore specific antibody. (trea.com)
  • Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. (justia.com)
  • The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. (patsnap.com)
  • Antibody therapy has been established for the targeted treatment of patients with cancer, immunological and angiogenic disorders. (justia.com)
  • Polakis, P. Arming antibodies for cancer therapy. (justia.com)
  • An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). (patsnap.com)
  • In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. (patsnap.com)
  • Hydroxychloroquine has been used in pregnant women who have anti-SSA/Ro antibodies and who have previously given birth to a child with cardiac manifestations. (heraldopenaccess.us)
  • B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases. (patsnap.com)
  • Guia Esencial Para Los Contratos De Arrendamiento De editors, Joint Antibody, and example paradox mixed-effects taken on a computationally joint baseline of time-to-event parameters from the Medicare Current Beneficiary Survey( MCBS). (naturheilpraxis-gisbert-fussek.de)
  • Multivariable log-binomial generalized linear models were used to estimate prevalence ratios (PRs) with 95% CIs of HDV IgG antibody-positivity associated with determinants of interest (age, injection drug use [IDU], high-risk sexual behaviour). (cdc.gov)